Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia.,Journal of Gynecologic Oncology

当前位置： X-MOL 学术 › J. Gynecol. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia.
Journal of Gynecologic Oncology ( IF 3.9 ) Pub Date : 2023-12-18 , DOI: 10.3802/jgo.2024.35.e27
Xiaofeng Lv _{1,

2} , Lili Guo _{1,

2} , Changyu Wang _{1,

2}

Affiliation

To determine whether proactive molecular risk classifier for endometrial cancer (ProMisE) could be used to assess the prognosis of patients with atypical endometrial hyperplasia (AEH) or early-stage endometrial cancer (EC) treated with levonorgestrel-releasing intrauterine system (LNG-IUS).

中文翻译：

LNG-IUS 保留生育能力治疗的疗效与子宫内膜癌或不典型子宫内膜增生的不同 ProMisE 亚型相关。

确定子宫内膜癌主动分子风险分类器 (ProMisE) 是否可用于评估接受左炔诺孕酮宫内缓释系统 (LNG-IUS) 治疗的不典型子宫内膜增生 (AEH) 或早期子宫内膜癌 (EC) 患者的预后。

更新日期：2023-12-18

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>